Advances in molecular medicines have led to the identification of promising targets on cellular and molecular levels. These targets are located in extracellular and intracellular compartments. The effectiveness of nanomedicines in cancer therapy is limited in part by inadequate delivery and transport in tumor interstitium. Here at Optimum, we research the experimental approaches to improve nanomedicine delivery and transport in solid tumors, focusing on tumor priming technology due to its ease and practicality (accomplished with standard-of-care chemotherapy, such as paclitaxel) and tumor selectivity.
